To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer
A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer
Sponsor: Air Force Military Medical University, China
Listed as NCT03206684, this PHASE4 trial focuses on Cervical Cancer and remains ongoing. Sponsored by Air Force Military Medical University, China, it has been updated 7 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Sep 2019 — Nov 2020 [monthly]
Unknown Status PHASE4
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Air Force Military Medical University, China
For direct contact, visit the study record on ClinicalTrials.gov .